Search for: "Teva Branded Pharmaceutical Products R"
Results 61 - 80
of 96
Sorted by Relevance
|
Sort by Date
23 Apr 2011, 9:58 pm
In March 2010, Bayer put additional risk warnings on the European product label for the Yasmin pill but said at the time that the overall benefit-risk profile remained unchanged.Bayer said in its 2010 annual report that there were about 6,850 lawsuits pending in the United States with plaintiffs claiming they had suffered injuries from Bayer's Yasmin and Yaz pills or generic copies sold by Teva's Barr Laboratories. [read post]
14 Nov 2016, 9:16 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
8 Feb 2017, 3:09 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
15 Mar 2008, 7:00 am
India: Gene silencing: (Spicy IP), India: US Patent reform implications for Indian Pharma: (Spicy IP), India: Generic pharmaceutical industry in the spotlight: (International Law Office), India: Supreme Court refuses to stay a Gujarat High Court decision restraining Ranbaxy from airing its controversial ads directed against Paras Pharma's 'Moov' brand: (Spicy IP),India: Patents on ARV drugs could increase costs: (Generic Pharmaceuticals & IP),US:… [read post]
26 Oct 2020, 2:49 am
The summary of product characteristics provides for a mandatory premedication regime under which the drug must be combined with vitamin B 12, as also stated in patent EP 508. [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its thinking… [read post]
25 Jul 2008, 7:04 am
, (Daily Dose of IP), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop –… [read post]
18 Jul 2008, 8:34 am
: (Patent Circle), Tanzania to conduct study on impact of counterfeit medicines: (Afro-IP), US: New rules on generic biological medicines under US Congressional debate: (Intellectual Property Watch), Pharma & Biotech - Products Acular (Ketorolac) – US: CAFC rules against Apotex reverse doctrine of equivalents: Roche Palo Alto & Allergan, Inc v Apotex: (Patent Circle), Carbatrol (Carbamazapine) – US: Federal judge allows Corepharma to seek DJ that its… [read post]
29 Feb 2008, 8:00 am
: (creativecommons.org)Pharma & BiotechPharma & Biotech - GeneralScience Commons news: A commons-sense approach to winning the drug discovery lottery: (creativecommons.org),India: Hindu Business Line reports on why pharma companies are pushing for tax incentives: (Spicy IP), India: J Mitra gets injunction against Span Diagnostics in patent dispute before Delhi High Court over device used in detection of Hep C: (Generic Pharmaceuticals & IP), India: Patent Office… [read post]
16 Jan 2017, 5:44 pm
Teva Pharmaceuticals USA, Inc., et al. [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to dodge real… [read post]
23 Aug 2008, 1:23 am
: (Part 1 - SPICY IP), (Part 2 - SPICY IP) Global – Copyright International Federation of the Phonographic Industry (IFPI): ‘Three strikes’ effort hit worldwide home run: (Ars Technica), How to attribute a Creative Commons licensed work: (Molly Kleinman), Chrysalis disappoints, as new artists fail to incubate: (IP finance), DRM for streaming music dies a quiet death: (Electronic Frontier Foundation), (Techdirt) Events 26 August:… [read post]
28 Sep 2016, 8:39 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
19 Sep 2008, 6:00 pm
: (Wired) The South strikes back against overreaching IP enforcement: (Intellectual Property Watch) WIPO assembly set to appoint new head: (Managing Intellectual Property) Open business systems fill gap in mainstream entertainment industry: (Intellectual Property Watch) Global - Trade Marks / Domain Names / Brands Brand values collapse in the face of global financial turmoil: (IAM), Genericness survey results: (Property, intangible) Reputation as risk: a lesson from the… [read post]
7 Mar 2008, 2:00 am
: (Techdirt) Global - Trade Marks / Domain Names / Brands UNCITRAL guidelines on IP securitization: the INTA’s response: (IP finance), Protection of geographical indications as part of WTO Doha Round negotiations? [read post]
4 Apr 2008, 1:00 am
: (IPBiz) Pharma & Biotech - Products Abilify (Aripiprazole) – Otsuka files US patent infringement suit against Teva over seeking approval for generic Abilify: (IP Law360), Aricept (Donepezil) – US federal judge grants Eisai’s request for preliminary injunction blocking Teva from marketing generic version of Aricept: (IP Law360), (Orange Book Blog), Carbatrol (Carbamazepine) – US federal judge delivers mixed… [read post]
11 Jul 2008, 4:30 am
, (Daily Dose of IP), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South Africa): (Afro-IP), 15-16 September: US ACI 10th advanced forum on biotech… [read post]
5 Jul 2008, 11:05 am
: (Intellectual Property Watch), Why compulsory licenses are bad: a look at the sausage making process: (Techdirt) More on ACTA: (LawFont.com) Global - Trade Marks / Domain Names / Brands Brand Finance 500: the annual report on the world’s most valuable brands: (IP finance), Gretchen Olive’s ‘10 steps to an effective domain name policy’: (IPwar’s), ICANN approves GNSO proposals imposing financial penalty on registrars who… [read post]
29 Aug 2008, 1:25 pm
: (IP finance), Facebook removes international access to Scrabulous, except from India: (Ars Technica), (Techdirt), Reverse engineering can resolve conflict between standardisation and competition: (Techdirt), Benefits of piracy aren’t always in the expected places: (Techdirt) Events 1-3 September: Federation of Indian Chambers of Commerce and Industry, Department of Industrial Property and Promotion, and WIPO conference on ‘Development and IP: Building synergies… [read post]
